{
    "root": "af1b3de0-9c50-407d-a154-afd07d4cd731",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Atorvastatin Calcium",
    "value": "20240613",
    "ingredients": [
        {
            "name": "ATORVASTATIN CALCIUM TRIHYDRATE",
            "code": "48A5M73Z4Q"
        },
        {
            "name": "CALCIUM CARBONATE",
            "code": "H0G9379FGK"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (90000 WAMW)",
            "code": "UKE75GEA7F"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        }
    ],
    "indications": "Atorvastatin calcium tablets are indicated:\n                  • To reduce the risk of:\n                    ○ Myocardial infarction (MI), stroke, revascularization procedures, and angina in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD\n                    ○ MI and stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident CHD\n                    ○ Non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure, and angina in adults with clinically evident CHD\n                  • As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in:\n                    ○ Adults with primary hyperlipidemia.\n                    ○ Adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH).\n                  • As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia (HoFH).\n                  • As an adjunct to diet for the treatment of adults with:\n                    ○ Primary dysbetalipoproteinemia\n                    ○ Hypertriglyceridemia",
    "contraindications": "• Take orally once daily with or without food ( 2.1 ). • Assess LDL-C when clinically appropriate, as early as 4 weeks after initiating atorvastatin calcium tablets, and adjust dosage if necessary ( 2.1 ). • Adults ( 2.2 ): ○ Recommended starting dosage is 10 or 20 mg once daily; dosage range is 10 mg to 80 mg once daily. ○ Patients requiring LDL-C reduction >45% may start at 40 mg once daily. • Pediatric Patients Aged 10 Years of Age and Older with HeFH : Recommended starting dosage is 10 mg once daily; dosage range is 10 to 20 mg once daily ( 2.3 ). • Pediatric Patients Aged 10 Years of Age and Older with HoFH : Recommended starting dosage is 10 to 20 mg once daily; dosage range is 10 to 80 mg once daily ( 2.4 ). • See full prescribing information for atorvastatin calcium tablets dosage modifications due to drug interactions ( 2.5 ).",
    "warningsAndPrecautions": "Atorvastatin calcium tablets, USP 20 mg tablets are white to off-white, film-coated, oval shaped tablet plain on one side and debossed with '114' on other side. They are available as follows:\n                  \n                  NDC: 71335-2404-1: 30 Tablets in a BOTTLE\n                  NDC: 71335-2404-2: 60 Tablets in a BOTTLE\n                  NDC: 71335-2404-3: 90 Tablets in a BOTTLE\n                  NDC: 71335-2404-4: 9 Tablets in a BOTTLE\n                  NDC: 71335-2404-5: 28 Tablets in a BOTTLE\n                  NDC: 71335-2404-6: 20 Tablets in a BOTTLE\n                  NDC: 71335-2404-7: 180 Tablets in a BOTTLE\n                  NDC: 71335-2404-8: 100 Tablets in a BOTTLE\n                  NDC: 71335-2404-9: 7 Tablets in a BOTTLE\n                  \n                  Repackaged/Relabeled by:Bryant Ranch Prepack, Inc.Burbank, CA 91504",
    "adverseReactions": "Acute liver failure or decompensated cirrhosis [see Warnings and Precautions (5.3)]\n                     \n                     Hypersensitivity to atorvastatin or any excipients in atorvastatin. Hypersensitivity reactions, including anaphylaxis, angioneurotic edema, erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis, have been reported [see Adverse\n                        Reactions (6.2)]."
}